156 related articles for article (PubMed ID: 33461473)
1. Application of Diffusion Weighted Imaging in Prostate Cancer Bone Metastasis: Detection and Therapy Evaluation.
Gong XQ; Tao YY; Wang R; Liu N; Huang XH; Zheng J; Yang C; Yang L; Zhang XM
Anticancer Agents Med Chem; 2021; 21(15):1950-1956. PubMed ID: 33461473
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
Perez-Lopez R; Mateo J; Mossop H; Blackledge MD; Collins DJ; Rata M; Morgan VA; Macdonald A; Sandhu S; Lorente D; Rescigno P; Zafeiriou Z; Bianchini D; Porta N; Hall E; Leach MO; de Bono JS; Koh DM; Tunariu N
Radiology; 2017 Apr; 283(1):168-177. PubMed ID: 27875103
[TBL] [Abstract][Full Text] [Related]
4. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
[TBL] [Abstract][Full Text] [Related]
5. Comparison of
Gauthé M; Zarca K; Aveline C; Lecouvet F; Balogova S; Cussenot O; Talbot JN; Durand-Zaleski I
BMC Med Imaging; 2020 Mar; 20(1):25. PubMed ID: 32122345
[TBL] [Abstract][Full Text] [Related]
6. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
8. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
9. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
Lee KC; Bradley DA; Hussain M; Meyer CR; Chenevert TL; Jacobson JA; Johnson TD; Galban CJ; Rehemtulla A; Pienta KJ; Ross BD
Neoplasia; 2007 Dec; 9(12):1003-11. PubMed ID: 18084607
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.
Jacobs MA; Macura KJ; Zaheer A; Antonarakis ES; Stearns V; Wolff AC; Feiweier T; Kamel IR; Wahl RL; Pan L
Acad Radiol; 2018 Nov; 25(11):1405-1414. PubMed ID: 29627288
[TBL] [Abstract][Full Text] [Related]
11. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Caglar M; Tuncel M; Yildiz E; Karabulut E
Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741
[TBL] [Abstract][Full Text] [Related]
12. Pilot study on the detection of antiandrogen resistance using serial diffusion-weighted imaging of bone metastases in prostate cancer.
Reischauer C; Koh DM; Froehlich JM; Patzwahl R; Binkert CA; Gutzeit A
J Magn Reson Imaging; 2016 Jun; 43(6):1407-16. PubMed ID: 26587694
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bone scintigraphy and
Pyka T; Okamoto S; Dahlbender M; Tauber R; Retz M; Heck M; Tamaki N; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2114-2121. PubMed ID: 27290607
[TBL] [Abstract][Full Text] [Related]
14. Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences.
Larbi A; Omoumi P; Pasoglou V; Michoux N; Triqueneaux P; Tombal B; Cyteval C; Lecouvet FE
Eur Radiol; 2019 Aug; 29(8):4503-4513. PubMed ID: 30413957
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of
Zacho HD; Nielsen JB; Afshar-Oromieh A; Haberkorn U; deSouza N; De Paepe K; Dettmann K; Langkilde NC; Haarmark C; Fisker RV; Arp DT; Carl J; Jensen JB; Petersen LJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
[TBL] [Abstract][Full Text] [Related]
16. METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer.
Yoshida S; Takahara T; Ishii C; Arita Y; Waseda Y; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
Clin Genitourin Cancer; 2020 Aug; 18(4):e391-e396. PubMed ID: 31902713
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients.
Heck MM; Souvatzoglou M; Retz M; Nawroth R; Kübler H; Maurer T; Thalgott M; Gramer BM; Weirich G; Rondak IC; Rummeny EJ; Schwaiger M; Gschwend JE; Krause B; Eiber M
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):694-701. PubMed ID: 24297503
[TBL] [Abstract][Full Text] [Related]
18. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
[TBL] [Abstract][Full Text] [Related]
19.
Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
